Key result
Plasma PICP levels were significantly elevated in patients with rheumatic mitral valve disease and served as a strong diagnostic marker with an AUC of 0.95.
Why the study?
Can markers of collagen metabolism (PICP, PIIINP, MMP-1, TIMP-1) be used to diagnose or monitor disease progression in patients with rheumatic mitral valve disease?
Case-Control (n=118)
No
Can markers of collagen metabolism (PICP, PIIINP, MMP-1, TIMP-1) be used to diagnose or monitor disease progression in patients with rheumatic mitral valve disease?
Effect estimate: AUC 0.95 (95% CI 0.91-0.99)
p-value: p=<0.0001
Plasma PICP is a highly sensitive and specific biomarker for diagnosing rheumatic heart disease and correlates with echocardiographic severity parameters.
Collagen markers may aid RHD diagnosis; case-control data leave open need for prospective validation.
BACKGROUND: Rheumatic Heart Disease (RHD), a chronic acquired heart disorder results from Acute Rheumatic Fever. It is a major public health concern in developing countries. In RHD, mostly the valves get affected. The present study investigated whether extracellular matrix remodelling in rheumatic valve leads to altered levels of collagen metabolism markers and if such markers can be clinically used to diagnose or monitor disease progression. METHODOLOGY: This is a case control study comprising 118 subjects. It included 77 cases and 41 healthy controls. Cases were classified into two groups- Mitral Stenosis (MS) and Mitral Regurgitation (MR). Carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), total Matrix Metalloproteinase-1(MMP-1) and Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) were assessed. Histopathology studies were performed on excised mitral valve leaflets. A p value <0.05 was considered statistically significant. RESULTS: Plasma PICP and PIIINP concentrations increased significantly (p<0.01) in MS and MR subjects compared to controls but decreased gradually over a one year period post mitral valve replacement (p<0.05). In MS, PICP level and MMP-1/TIMP-1 ratio strongly correlated with mitral valve area (r = -0.40; r = 0.49 respectively) and pulmonary artery systolic pressure (r = 0.49; r = -0.49 respectively); while in MR they correlated with left ventricular internal diastolic (r = 0.68; r = -0.48 respectively) and systolic diameters (r = 0.65; r = -0.55 respectively). Receiver operating characteristic curve analysis established PICP as a better marker (AUC = 0.95; 95% CI = 0.91-0.99; p<0.0001). A cut-off >459 ng/mL for PICP provided 91% sensitivity, 90% specificity and a likelihood ratio of 9 in diagnosing RHD. Histopathology analysis revealed inflammation, scarring, neovascularisation and extensive leaflet fibrosis in diseased mitral valve. CONCLUSIONS: Levels of collagen metabolism markers correlated with echocardiographic parameters for RHD diagnosis.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2014) conducted a case-control in Rheumatic Mitral Valve Disease (n=118). Rheumatic Mitral Valve Disease vs. Healthy controls was evaluated on Diagnostic accuracy of plasma PICP for rheumatic heart disease (AUC 0.95, 95% CI 0.91-0.99, p=<0.0001). Plasma PICP levels were significantly elevated in patients with rheumatic mitral valve disease and served as a strong diagnostic marker with an AUC of 0.95.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: